Literature DB >> 15247626

Functional responses of human beta1 adrenoceptors with defined haplotypes for the common 389R>G and 49S>G polymorphisms.

Alastair Sandilands1, Giles Yeo, Morris J Brown, Kevin M O'Shaughnessy.   

Abstract

OBJECTIVES: The human beta1-adrenoceptor (beta1-AR) is an important therapeutic target for cardiovascular diseases and has two common functional polymorphisms (49S>G and 389R>G). These polymorphisms have only been studied in isolation, however, and not in the context of the four haplotypes (SR, SG, GR and GG) that exist in native beta1-ARs.
METHODS: To address this, the function of each of the receptor haplotypes was studied in HEK 293 cells stably transfected with appropriately modified human beta1-adrenoceptor cDNA sequence.
RESULTS: The affinity for the beta-adrenoceptor ligand, [125I]-cyanopindolol, was not significantly different across the haplotypes, but a high affinity state for the beta1-AR could only be demonstrated for receptors carrying the 389R substitution. Both basal (GR 36.3 +/- 2.9* vs. SR 16.5 0 +/- 3.6 and GG 31.7 +/- 1.4* vs. SG 15.6 +/- 1.5 pmol/mg protein; *P < 0.001) and maximal (GR 163 +/- 7.6 vs. SR 124 +/- 8.1* and GG 75.0 +/- 1.0 vs. SG 52.4 +/- 1.1* pmol/mg protein; *P < 0.001) isoprenaline-evoked cAMP production was significantly affected by both substitutions. Incubation with isoprenaline (10 microm for 30 min or 20 h) caused increased down-regulation of beta1-ARs in cells expressing GG and GR haplotypes (at 20 h percentage fall respectively -28.1 +/- 5.2 and -38.2 +/- 3.0).
CONCLUSIONS: These data highlight important functional differences between the common beta1-AR haplotypes and the need for consideration of haplotypes and not individual genotypes in determining the in-vivo role of these polymorphisms within this important drug target.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247626     DOI: 10.1097/00008571-200406000-00003

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  16 in total

1.  Confirmation of a role for the 389R>G beta-1 adrenoceptor polymorphism on exercise capacity in heart failure.

Authors:  A J Sandilands; J Parameshwar; S Large; M J Brown; K M O'Shaughnessy
Journal:  Heart       Date:  2005-12       Impact factor: 5.994

2.  Progression of chronic kidney disease: Adrenergic genetic influence on glomerular filtration rate decline in hypertensive nephrosclerosis.

Authors:  Yuqing Chen; Michael S Lipkowitz; Rany M Salem; Maple M Fung; Vibha Bhatnagar; Manjula Mahata; Caroline M Nievergelt; Fangwen Rao; Sushil K Mahata; Nicholas J Schork; Pamela J Hicks; Donald W Bowden; Barry I Freedman; Victoria H Brophy; Daniel T O'Connor
Journal:  Am J Nephrol       Date:  2010-05-19       Impact factor: 3.754

Review 3.  Beta-adrenoceptor blocker treatment and the cardiac beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure.

Authors:  Otto-Erich Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-11       Impact factor: 3.000

4.  S49G and R389G polymorphisms of the β₁-adrenergic receptor influence signaling via the cAMP-PKA and ERK pathways.

Authors:  Fan Zhang; Susan F Steinberg
Journal:  Physiol Genomics       Date:  2013-10-22       Impact factor: 3.107

Review 5.  The functional significance of genetic variation within the beta-adrenoceptor.

Authors:  A J Sandilands; K M O'Shaughnessy
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

6.  Roles of beta2- and beta3-adrenoceptor polymorphisms in hypertension and metabolic syndrome.

Authors:  Kazuko Masuo
Journal:  Int J Hypertens       Date:  2010-10-21       Impact factor: 2.420

7.  Beta1-adrenoceptor polymorphism predicts flecainide action in patients with atrial fibrillation.

Authors:  Amir M Nia; Evren Caglayan; Natig Gassanov; Tom Zimmermann; Orhan Aslan; Martin Hellmich; Firat Duru; Erland Erdmann; Stephan Rosenkranz; Fikret Er
Journal:  PLoS One       Date:  2010-07-02       Impact factor: 3.240

Review 8.  Beta 1- and beta 2-adrenoceptor polymorphisms and cardiovascular diseases.

Authors:  Kirsten Leineweber; Gerd Heusch
Journal:  Br J Pharmacol       Date:  2009-05-05       Impact factor: 8.739

9.  beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension.

Authors:  M A Pacanowski; Y Gong; R M Cooper-Dehoff; N J Schork; M D Shriver; T Y Langaee; C J Pepine; J A Johnson
Journal:  Clin Pharmacol Ther       Date:  2008-07-09       Impact factor: 6.875

10.  Adrenergic beta-1 receptor genetic variation predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis.

Authors:  Maple M Fung; Yuqing Chen; Michael S Lipkowitz; Rany M Salem; Vibha Bhatnagar; Manjula Mahata; Caroline M Nievergelt; Fangwen Rao; Sushil K Mahata; Nicholas J Schork; Victoria H Brophy; Daniel T O'Connor
Journal:  Nephrol Dial Transplant       Date:  2009-09-10       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.